Table 1.
Demographics of BC patients in the imaging-subtype discovery and validation cohorts. The detailed clinical, imaging, and molecular data for the discovery and validation of radiomics cohorts. The patient distribution of the two cohorts was not different except for the PAM50 molecular subtypes.
| Characteristics | Discovery Cohort (n = 174) |
Validation Cohort (n = 72) |
p-Value |
|---|---|---|---|
| Age, mean (SD) | ≤50 years:95/>50 years:79; 49.78 years (9.99) |
≤50 years:30/>50 years:42; 53.96 years (11.75) |
0.088 a |
| Histopathology type | 0.069 a | ||
| Ductal | 156 | 71 | |
| Lobular | 4 | 0 | |
| Mixed | 12 | 0 | |
| Other | 2 | 1 | |
| BI-RADS | NA | ||
| Category 3 | 1 | NA | |
| Category 4 | 61 | NA | |
| Category 5 | 103 | NA | |
| Category 6 | 9 | NA | |
| IHC receptors | |||
| ER status | P:127/N:47 | P:61/N:11 | 0.071 a |
| PR status | P:111/N:63 | P:55/N:17 | 0.077 a |
| HER2 status | P:36/N:138 | P:14 / N:37/NA:21 | 0.407 a |
| Ki67 status | high:136/low:38 | NA | NA |
| IHC-based subtype | |||
| Luminal-A | 28 | NA | NA |
| Luminal-B | 101 | NA | NA |
| HER2-positive | 15 | NA | NA |
| Triple-negative | 30 | NA | NA |
| PAM50 subtype | <0.001 a | ||
| Luminal-A | 49 | 44 | |
| Luminal-B | 43 | 9 | |
| HER2-Enriched | 29 | 5 | |
| Basal-like | 43 | 10 | |
| Normal-like | 10 | 4 | |
| Pathological stage | 0.267 a | ||
| Stage I | 55 | 17 | |
| Stage II | 94 | 47 | |
| Stage III | 25 | 8 |
Note: unless otherwise indicated, data are the number of patients or the p-value of the statistical test. a p-value for the two-sided Pearson’s chi-squared test. SD, standard deviation; P, positive receptor status; N, negative. BI-RADS, Breast Imaging-Reporting and Data System. NA: not available.